These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

547 related items for PubMed ID: 20587123

  • 41. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy.
    Madi N, Altawalah H, Alfouzan W, Al-Nakib W, Al-Roumi E, Jeragh A.
    J Med Virol; 2020 Aug; 92(8):963-970. PubMed ID: 31919861
    [Abstract] [Full Text] [Related]

  • 42. The epidemiology of rubella in England and Wales before and after the 1994 measles and rubella vaccination campaign: fourth joint report from the PHLS and the National Congenital Rubella Surveillance Programme.
    Miller E, Waight P, Gay N, Ramsay M, Vurdien J, Morgan-Capner P, Hesketh L, Brown D, Tookey P, Peckham C.
    Commun Dis Rep CDR Rev; 1997 Feb 07; 7(2):R26-32. PubMed ID: 9046126
    [Abstract] [Full Text] [Related]

  • 43. Cost effectiveness of prevaccination screening of health care workers for immunity to measles, rubella and mumps.
    Ferson MJ, Robertson PW, Whybin LR.
    Med J Aust; 1994 Apr 18; 160(8):478-82. PubMed ID: 8170422
    [Abstract] [Full Text] [Related]

  • 44. Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?
    Celikbas A, Ergonul O, Aksaray S, Tuygun N, Esener H, Tanir G, Eren S, Baykam N, Guvener E, Dokuzoguz B.
    Am J Infect Control; 2006 Nov 18; 34(9):583-7. PubMed ID: 17097453
    [Abstract] [Full Text] [Related]

  • 45. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, Markowitz LE.
    J Infect Dis; 2004 May 01; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [Abstract] [Full Text] [Related]

  • 46. Seroprevalence and Determinants Associated with Mumps Antibodies after 20 Years of MMR Vaccination in Urban Area of Shanghai, China.
    Pang H, Zhou Y, Zhao W, Jiang Q.
    Int J Environ Res Public Health; 2018 Sep 23; 15(10):. PubMed ID: 30249033
    [Abstract] [Full Text] [Related]

  • 47. Assessing seropositivity of MMR antibodies in individuals aged 2-22: evaluating routine vaccination effectiveness after the 2003 mass campaign-a study from Iran's National Measles Laboratory.
    Ghafoori F, Mokhtari-Azad T, Foroushani AR, Farahmand M, Shadab A, Salimi V.
    BMC Infect Dis; 2024 Jul 12; 24(1):696. PubMed ID: 38997625
    [Abstract] [Full Text] [Related]

  • 48. Seroprevalence of measles, mumps and rubella among young adults, after 20 years of universal 2-dose MMR vaccination in Israel.
    Levine H, Zarka S, Ankol OE, Rozhavski V, Davidovitch N, Aboudy Y, Balicer RD.
    Hum Vaccin Immunother; 2015 Jul 12; 11(6):1400-5. PubMed ID: 25891446
    [Abstract] [Full Text] [Related]

  • 49. Vaccination update. Diphtheria, tetanus, pertussis, mumps, rubella, measles.
    Vetter RT, Johnson GM.
    Postgrad Med; 1995 Oct 12; 98(4):133-7, 141-2, 144-5 passim. PubMed ID: 7567714
    [Abstract] [Full Text] [Related]

  • 50. [Evolution of measles, rubella and mumps from the third seroepidemiological survey in the autonomous region of Madrid, Spain].
    Sanz Moreno JC, García Comas L, Ramírez Fernández R, Ramos Blázquez B, Ordobás Gavín M.
    Rev Esp Salud Publica; 2009 Oct 12; 83(5):625-37. PubMed ID: 20111811
    [Abstract] [Full Text] [Related]

  • 51. Incidence of mumps and immunity to measles, mumps and rubella among US military recruits, 2000-2004.
    Eick AA, Hu Z, Wang Z, Nevin RL.
    Vaccine; 2008 Jan 24; 26(4):494-501. PubMed ID: 18155326
    [Abstract] [Full Text] [Related]

  • 52. Seroepidemiology of measles, mumps and rubella virus infections in normal children and adults in southern Granada, Spain: response to a vaccination programme.
    Gutiérrez J, Rodríguez M, Huber E, Muñoz A, Piédrola G, Maroto C.
    Microbios; 1996 Jan 24; 88(356):143-8. PubMed ID: 9141711
    [Abstract] [Full Text] [Related]

  • 53. Safety concerns regarding combination vaccines: the experience in Japan.
    Andreae MC, Freed GL, Katz SL.
    Vaccine; 2004 Sep 28; 22(29-30):3911-6. PubMed ID: 15364439
    [Abstract] [Full Text] [Related]

  • 54. Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity.
    Poethko-Müller C, Mankertz A.
    PLoS One; 2012 Sep 28; 7(8):e42867. PubMed ID: 22880124
    [Abstract] [Full Text] [Related]

  • 55. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T, Baer M, Willems P.
    Pediatr Infect Dis J; 2007 Feb 28; 26(2):153-8. PubMed ID: 17259879
    [Abstract] [Full Text] [Related]

  • 56. Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants.
    Yerkovich ST, Rowe J, Richmond P, Suriyaarachchi D, Heaton T, Hollams E, Ladyman C, Serralha M, Sadowska A, Loh R, Wesselingh SL, Sly PD, Holt PG.
    Vaccine; 2007 Feb 26; 25(10):1764-70. PubMed ID: 17224218
    [Abstract] [Full Text] [Related]

  • 57. Vaccine preventable diseases in the United States, 1996.
    Commun Dis Rep CDR Wkly; 1997 Sep 26; 7(39):347, 350. PubMed ID: 9345809
    [No Abstract] [Full Text] [Related]

  • 58. Measles, Mumps, and Rubella Serostatus and Response to MMR Vaccination Among HIV-Infected Adults.
    Singh HK, Chiu YL, Wilkin T.
    AIDS Patient Care STDS; 2015 Sep 26; 29(9):461-4. PubMed ID: 26153909
    [No Abstract] [Full Text] [Related]

  • 59. Progress towards measles and rubella elimination in Tuscany, Italy: the role of population seroepidemiological profile.
    Bechini A, Boccalini S, Tiscione E, Pesavento G, Mannelli F, Peruzzi M, Rapi S, Mercurio S, Bonanni P.
    Eur J Public Health; 2012 Feb 26; 22(1):133-9. PubMed ID: 20880991
    [Abstract] [Full Text] [Related]

  • 60. Using Locally Derived Seroprevalence Data on Measles, Mumps, Rubella, and Varicella by Birth Cohort to Determine Risks for Vaccine-Preventable Diseases During International Travel.
    Rosario-Rosario G, Gareca M, Kincaid H, Knouse MC.
    J Travel Med; 2015 Feb 26; 22(6):396-402. PubMed ID: 26412393
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.